|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM364269618 |
| 003 |
DE-627 |
| 005 |
20240209231949.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202307818
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1285.xml
|
| 035 |
|
|
|a (DE-627)NLM364269618
|
| 035 |
|
|
|a (NLM)37935201
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Chen, Mengqi
|e verfasserin
|4 aut
|
| 245 |
1 |
3 |
|a An "AND" Logic-Gated Prodrug Micelle Locally Stimulates Antitumor Immunity
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.02.2024
|
| 500 |
|
|
|a Date Revised 09.02.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Materials that can respond to multiple biomarkers simultaneously, acting as an "AND" gate, have the potential to enhance tumor-targeting for drug delivery. In this study, an "AND" logic-controlled release prodrug micelle is developed for codelivering the chemotherapeutic and the stimulator of interferon genes (STING) agonist, enabling precise combinatorial therapy. The drug release is programmed by tumor-enriched boramino acids (BAA) in the tumor microenvironment and intracellular reactive oxygen species (ROS), resulting in enhanced tumor targeting. STING agonist is successfully encapsulated into prodrug micelles through π-π stacking and hydrophobic interactions. These AND logic-gated prodrug micelles can achieve tumor-targeted delivery of STING agonist, leading to significantly enhanced immune activation and antitumor efficacy in vivo. It is expected that this clinically relevant nanoplatform will provide a rational design of an effective immunotherapy combination regimen to convert immunologically "cold" tumors to immunogenic "hot" tumors, addressing the major challenges faced by immunotherapies
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a AND logic
|
| 650 |
|
4 |
|a controlled drug release
|
| 650 |
|
4 |
|a precise cancer therapy
|
| 650 |
|
7 |
|a Prodrugs
|2 NLM
|
| 650 |
|
7 |
|a Micelles
|2 NLM
|
| 700 |
1 |
|
|a Wang, Chunhong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Xuanyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tu, Zhiyu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ding, Zexuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Zhibo
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 6 vom: 06. Feb., Seite e2307818
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:6
|g day:06
|g month:02
|g pages:e2307818
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202307818
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 6
|b 06
|c 02
|h e2307818
|